New Delhi: The Drugs Controller General of India (DCGI), the national  regulator,  after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group of 2 to 18 years, to its manufacturer Bharat Biotech Ltd. The Hyderabad-…